|
[1]
|
Glycosylation of OVA antigen-loaded PLGA nanoparticles enhances DC-targeting for cancer vaccination
Journal of Controlled Release,
2022
DOI:10.1016/j.jconrel.2022.10.002
|
|
|
|
|
[2]
|
Glycosylation of OVA antigen-loaded PLGA nanoparticles enhances DC-targeting for cancer vaccination
Journal of Controlled Release,
2022
DOI:10.1016/j.jconrel.2022.10.002
|
|
|
|
|
[3]
|
An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery
Pharmaceutics,
2021
DOI:10.3390/pharmaceutics13040455
|
|
|
|
|
[4]
|
Nucleic Acid-Based Approaches for Tumor Therapy
Cells,
2020
DOI:10.3390/cells9092061
|
|
|
|
|
[5]
|
Using nanoparticles for in situ vaccination against cancer: mechanisms and immunotherapy benefits
International Journal of Hyperthermia,
2020
DOI:10.1080/02656736.2020.1802519
|
|
|
|
|
[6]
|
Cationic polymers for enhancing CpG oligodeoxynucleotides-mediated cancer immunotherapy
European Polymer Journal,
2019
DOI:10.1016/j.eurpolymj.2018.12.044
|
|
|
|
|
[7]
|
Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect
Immunology Letters,
2018
DOI:10.1016/j.imlet.2018.06.004
|
|
|
|
|
[8]
|
Polymer nanoparticles as adjuvants in cancer immunotherapy
Nano Research,
2018
DOI:10.1007/s12274-018-2124-7
|
|
|
|
|
[9]
|
Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences
Journal of Controlled Release,
2018
DOI:10.1016/j.jconrel.2018.07.011
|
|
|
|
|
[10]
|
Delivery of therapeutics with nanoparticles: what's new in cancer immunotherapy?
WIREs Nanomedicine and Nanobiotechnology,
2017
DOI:10.1002/wnan.1421
|
|
|
|
|
[11]
|
Delivery of therapeutics with nanoparticles: what's new in cancer immunotherapy?
WIREs Nanomedicine and Nanobiotechnology,
2017
DOI:10.1002/wnan.1421
|
|
|
|
|
[12]
|
DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy
Pharmacology & Therapeutics,
2016
DOI:10.1016/j.pharmthera.2016.05.004
|
|
|
|
|
[13]
|
Targeting myeloid cells using nanoparticles to improve cancer immunotherapy
Advanced Drug Delivery Reviews,
2015
DOI:10.1016/j.addr.2014.09.007
|
|
|
|
|
[14]
|
The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy
Cancer Gene Therapy,
2015
DOI:10.1038/cgt.2015.2
|
|
|
|
|
[15]
|
Enhancement of anti-tumor effect of particulate vaccine delivery system by ‘bacteriomimetic’ CpG functionalization of poly-lactic-co-glycolic acid nanoparticles
Nanomedicine,
2015
DOI:10.2217/nnm.14.144
|
|
|
|
|
[16]
|
Recent progress concerning CpG DNA and its use as a vaccine adjuvant
Expert Review of Vaccines,
2014
DOI:10.1586/14760584.2014.863715
|
|
|
|